文献速递免疫规划传染病防控与疫情报告

日本甲型H3N2候选疫苗株免疫原性比较:随机对照试验

Comparison of immunogenicity between candidate influenza A(H3N2) virus vaccine strains in Japan: A randomized controlled trial using a monovalent vaccine of A/Saitama/103/2014 (CEXP-002) and A/Hong Kong/4801/2014 (X-263).
PubMed 文献 · Vaccine · 2020-08-29

该随机对照试验将100名20-64岁健康成人分为两组,分别接种含Saitama株或Hong Kong株的单价甲型H3N2疫苗。结果显示Hong Kong疫苗诱导的免疫原性优于或等同于Saitama疫苗,且实验模型中的抗原相似性不一定与人群免疫原性相关。

要点

  • Hong Kong疫苗对同源株的接种后GMT显著高于Saitama疫苗。
  • Hong Kong疫苗对Saitama株的GMT和SPP显著更高。
  • 对循环株A/Osaka/188/2017,Hong Kong疫苗的SCP和SPP显著更高。

核心结论

  • Hong Kong疫苗诱导的免疫原性优于或等同于Saitama疫苗。
  • 实验模型中的抗原相似性不一定与人群免疫原性相关。

研究设计与样本

  • 随机对照试验,纳入100名20-64岁健康成人,每组50人。
  • 分别接种含Saitama株或Hong Kong株的单价甲型H3N2疫苗。
  • 采用病毒中和试验检测第0天和第21天血清。

主要发现

  • 对Hong Kong株,Hong Kong疫苗接种者接种后GMT为1:546,Saitama疫苗接种者为1:260,p<0.01。
  • 对Saitama株,Hong Kong疫苗接种者接种后GMT为1:116,Saitama疫苗接种者为1:61,p=0.01;SPP分别为86%和68%,p=0.03。
  • 对A/Osaka/188/2017株,Hong Kong疫苗接种者SCP为32%,Saitama疫苗接种者为4%,p<0.01;SPP分别为28%和6%,p<0.01。

临床怎么用

  • 选择疫苗株时需关注人群免疫原性数据,不能仅依赖实验模型抗原相似性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For the 2017-18 influenza season, A/Saitama/103/2014 (CEXP-002) (Saitama strain) was antigenically more similar to prior circulating strains than A/Hong Kong/4801/2014 (X-263) (Hong Kong strain) in a ferret model and was selected as the A(H3N2) vaccine virus strain in Japan. However, the Saitama strain grew poorly, and the Japanese government switched to the Hong Kong strain, raising public concerns of poor effectiveness. To enhance understanding of the correlation between antigenicity in experimental models and immunogenicity, as a surrogate measure of vaccine effectiveness, in the human population, we compared the immunogenicity of specially-prepared single dose monovalent influenza A(H3N2) vaccines containing the Saitama or the Hong Kong strain. METHODS: A randomized controlled trial of 100 healthy adults aged 20-64 years (n = 50/group) was conducted. Virus neutralization assay was performed on sera from days 0 (pre-vaccination) and 21 (post-vaccination). Geometric mean titer (GMT), mean fold rise (MFR), seroconversion proportion (SCP), and seroprotection proportion (SPP) were calculated for vaccine strains and a representative circulating A(H3N2) virus strain (A/Osaka/188/2017). RESULTS: For the Hong Kong strain, post-vaccination GMT was significantly higher in the Hong Kong vaccine recipients (1:546 vs 1:260, p < 0.01), but MFR, SCP, and SPP were similar for both vaccine groups. For the Saitama strain, post-vaccination GMT (1:116 vs 1:61, p = 0.01) and SPP (86% vs 68%, p = 0.03) were significantly higher in the Hong Kong vaccine recipients, but MFR and SCP were similar for both vaccine groups. Against A/Osaka/188/2017, post-vaccination GMT and MFR were similar in both vaccine groups, but SCP (32% vs 4%, p < 0.01) and SPP (28% vs. 6%, p < 0.01) were significantly higher in the Hong Kong vaccine recipients. CONCLUSION: The Hong Kong vaccine induced better or equivalent immunogenicity in comparison to the Saitama vaccine. Our trial showed that antigenic similarity in experimental models does not necessarily correlate with immunogenicity in the human population. CLINICAL TRIAL REGISTRATION: UMIN000029293.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kase T, Inoue M, Morikawa S, et al. Comparison of immunogenicity between candidate influenza A(H3N2) virus vaccine strains in Japan: A randomized controlled trial using a monovalent vaccine of A/Saitama/103/2014 (CEXP-002) and A/Hong Kong/4801/2014 (X-263). Vaccine. 2020. PMID: 32873406. doi:10.1016/j.vaccine.2020.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。